Health Care · Surgical & Medical Instruments & Apparatus

MDLN Medline Inc SEC Filings & Insider Trading Activity 2026

company
CIK 204638691 filings

MDLN at a glance

Medline Inc (MDLN, SEC CIK 2046386) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 18, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Medline Inc (MDLN) reported revenue of $28.4 billion (up 11.5% from FY2024) and net income of $1.2 billion. Diluted EPS was -$0.01.
  • As of September 30, 2026, 36 institutional investment managers tracked by SignalX reported holding Medline Inc (MDLN) shares worth $16.1 billion in 13F-HR filings.
  • In the last 90 days, MDLN insiders reported 0 open-market purchases ($0) and 6 open-market sales ($996.4M) on Form 4, a net sale of $996.4M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$28.4B
+11.5% vs prior year
Insiders · 90 days
0 buys · 6 sells
Net −$996.4M
13F holders
36 funds
$16.1B · +0 vs prior quarter
Latest 8-K
Nov 18, 2026
Item 1.01 · Item 8.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 26, 2026

Risk Factors

  • No material changes to risk factors disclosed in the 2025 Form 10-K
  • Carried-forward risks remain unchanged for the quarter

Management Discussion & Analysis

  • Quarterly revenue $7,856M, up 10.4% YoY from $7,115M, driven by organic volume growth
  • Gross margin 24.5% vs 26.4% YoY; net income margin 4.0% vs 4.5%; Adjusted EBITDA margin 12.2% vs 12.1%
  • Best segment: Medline Brand revenue $3,637M, up 6.6%, EBITDA margin 25.9% vs 24.1%; worst: Supply Chain Solutions margin 4.4% vs 5.5%
  • Cash and equivalents $2,321M, short-term investments $1,287M; nine-month operating cash flow $2,152M vs $1,515M
  • Headwinds: tariffs, FDA bed recall costs $60M to $210M, restructuring costs $20M to $30M; 2026 capital expenditures up to $600M

AI summary of the MDLN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 18, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • $200 million private repurchase of Class A shares and Medline Holdings Common Units from major institutional stockholders
  • Repurchase price equal to the Offering underwriting price, aligning transaction economics with the concurrent offering

Item 8.01: Other Events

  • Secondary offering of 60,000,000 Class A shares by selling stockholders
  • Approximately $2.1 billion net proceeds to selling stockholders, not Medline

Item EX-99.1: Item EX-99.1

  • Secondary offering priced at $35.50 per share for 60 million shares, with a 9 million-share underwriter option
  • Selling stockholders receive proceeds, not Medline, limiting dilution and providing no new corporate capital
Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Medline’s Q3 and first-nine-month results released for period ended September 26, 2026
  • Investors should review Exhibit 99.1 for revenue, earnings, margins and outlook details

Item EX-99.1: Item EX-99.1

  • Q3 net sales $7.9B, up 10.4%, while net income fell 1.2% to $318M, signaling growth with margin pressure
  • Q3 Adjusted EBITDA $960M, up 11.8%, but gross margin declined to 24.5% from 26.4%
Filed Oct 21, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Voluntary exit from all Medline Brand beds and related products, eliminating a Front Line Care product line
  • Affected products generated approximately $60 million in sales over the twelve months ended June 27, 2026

AI summaries of MDLN 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for MDLN

Don't miss the next MDLN filing

  • Alerts as it files. A push when MDLN files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut MDLN, by share count.
  • Ask anything. An AI agent that reads every MDLN filing and answers with sources.

MDLN alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
CP Circle ML Holdco GP, LLCJNov 18, 2026-
CP Circle ML Holdco GP, LLCCNov 18, 2026-
BX Mozart ML-1 Holdco L.P.CNov 18, 2026-
CP Circle ML Holdco GP, LLCCNov 18, 2026-
BX Mozart ML-1 Holdco L.P.JNov 18, 2026-
BX Mozart ML-1 Holdco L.P.JNov 18, 2026-
BX Mozart ML-1 Holdco L.P.CNov 18, 2026-
BX Mozart ML-1 Holdco L.P.CNov 18, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$23.2B$25.5B$28.4B
Gross Profit-$7.0B$7.5B
Operating Income$1.3B$2.1B$2.2B
Net Income-$1.2B$1.2B
Gross Margin-27.3%26.4%
Op. Margin5.4%8.4%7.8%
Net Margin-4.6%4.1%
Balance Sheet
Total Assets-$36.0B$38.5B
Equity--$10.7B
ROE--10.8%
Per Share
EPS--$-0.01
Cash Flow
Operating CF$1.7B$1.8B$1.7B
CapEx$275.0M$354.0M$447.0M

Source: XBRL data in Medline Inc (MDLN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate MDLN share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
MDLN shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202636$16.13B
Q2 202636$19.39B
Q1 202633$20.79B
Q4 202526$19.40B
Position changes: Q2 2026 → Q3 2026
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 131 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

MDLN filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 19, 2026--
4Nov 19, 2026--
4Nov 19, 2026--
4Nov 19, 2026--
4Nov 19, 2026--
4Nov 19, 2026--
4Nov 19, 2026--
8-KNov 18, 2026Analysis-
4Nov 16, 2026--
4Nov 16, 2026--
4Nov 16, 2026--
4Nov 16, 2026--
10-QNov 4, 2026Analysis
8-KNov 4, 2026Analysis-
8-KOct 21, 2026Analysis-
8-KOct 15, 2026Analysis-
4Oct 13, 2026--
4Oct 6, 2026--
4Aug 21, 2026--
4Aug 21, 2026--
4Aug 17, 2026--
4Aug 11, 2026--
4Aug 7, 2026--
4Aug 7, 2026--
8-KAug 5, 2026Analysis-

Related Health Care companies

All Health Care →

MDLN SEC filings: frequently asked questions

Are MDLN insiders buying or selling?

In the last 90 days, Medline Inc (MDLN) officers, directors and 10% owners reported no open-market purchases and 6 open-market sales worth $996.4 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold MDLN stock?

As of September 30, 2026, the largest Medline Inc (MDLN) holders among the 13F filers tracked by SignalX were Carlyle Group ($6.5 billion), Blackstone Group ($3.5 billion), Invesco Ltd ($1.4 billion), BlackRock ($921.3 million), Vanguard Capital Management LLC ($858.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was MDLN's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Medline Inc (MDLN) reported revenue of $28.4 billion (up 11.5% from FY2024) and net income of $1.2 billion. Diluted EPS was -$0.01. The figures come from the XBRL data in the 10-K.

What did MDLN report in its latest 8-K?

Medline Inc (MDLN) filed an 8-K on November 18, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement) and Item 8.01 (Other Events). $200 million private repurchase of Class A shares and Medline Holdings Common Units from major institutional stockholders.

What are the latest MDLN SEC filings?

Medline Inc (MDLN) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 18, 2026 and a Form 4 insider filing on November 19, 2026.

What is MDLN's SEC CIK number?

Medline Inc (MDLN)'s SEC Central Index Key (CIK) is 2046386. EDGAR lists every MDLN filing under that number.

Ask anything about MDLN

The research agent reads MDLN's filings, financials, insider trades and 13F holders, then answers with sources.